MXPA03006631A - Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares. - Google Patents

Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.

Info

Publication number
MXPA03006631A
MXPA03006631A MXPA03006631A MXPA03006631A MXPA03006631A MX PA03006631 A MXPA03006631 A MX PA03006631A MX PA03006631 A MXPA03006631 A MX PA03006631A MX PA03006631 A MXPA03006631 A MX PA03006631A MX PA03006631 A MXPA03006631 A MX PA03006631A
Authority
MX
Mexico
Prior art keywords
bile acid
absorption inhibitor
combinations
acid sequestrant
treatments
Prior art date
Application number
MXPA03006631A
Other languages
English (en)
Inventor
R Davis Harry
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA03006631A publication Critical patent/MXPA03006631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion provee composiciones, combinaciones terapeuticas y metodos, que incluyen: (a) por lo menos un secuestrante de los acidos biliares; y: (b) por lo menos una azatidinona sustituida o un ¦-lactama sustituido, que son inhibidores de la absorcion de los esteroles, que pueden ser utiles en el tratamiento de las condiciones vasculares, diabetes, obesidad, y para disminuir los niveles de los esteroles en el plasma.
MXPA03006631A 2001-01-26 2002-01-25 Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares. MXPA03006631A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26460001P 2001-01-26 2001-01-26
US32384201P 2001-09-21 2001-09-21
PCT/US2002/002010 WO2002058733A2 (en) 2001-01-26 2002-01-25 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Publications (1)

Publication Number Publication Date
MXPA03006631A true MXPA03006631A (es) 2004-03-18

Family

ID=26950649

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006631A MXPA03006631A (es) 2001-01-26 2002-01-25 Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.

Country Status (16)

Country Link
US (2) US20030053981A1 (es)
EP (2) EP1785144A3 (es)
JP (1) JP2004521894A (es)
AR (1) AR035739A1 (es)
AT (1) ATE369851T1 (es)
AU (1) AU2002241956A1 (es)
CA (1) CA2434033A1 (es)
CY (1) CY1106915T1 (es)
DE (1) DE60221798T2 (es)
DK (1) DK1363668T3 (es)
ES (1) ES2287250T3 (es)
MX (1) MXPA03006631A (es)
PT (1) PT1363668E (es)
SI (1) SI1363668T1 (es)
TW (1) TW200744638A (es)
WO (1) WO2002058733A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288217B6 (sk) * 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
CA2460340C (en) * 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003270909A1 (en) * 2002-09-27 2004-04-19 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
MXPA05009501A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
ATE406364T1 (de) * 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004094608A2 (en) * 2003-04-18 2004-11-04 Curagen Corporation Human procolipase like nucleic acids and polypeptides and their methods of use threof
US20070238717A1 (en) * 2003-10-21 2007-10-11 Johns Hopkins University Neuroprotection with Beta-Lactam Compounds
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
WO2005046662A2 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
DE602004029715D1 (de) 2003-12-23 2010-12-02 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
WO2007011886A2 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
WO2010113175A2 (en) 2009-04-01 2010-10-07 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
WO2011075539A2 (en) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of obesity or diabetes with bile acid sequestrants
TR201005327A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Sinerjik farmasötik formülasyonlar.
JP2017517550A (ja) 2014-06-13 2017-06-29 ユナイテッド セラピューティクス コーポレイション トレプロスチニル製剤

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
US1286A (en) * 1839-08-13 Richard else
US3108097A (en) * 1963-10-22 Ehnojs
BE578515A (es) * 1958-05-07
NL127065C (es) * 1964-04-22
NL137318C (es) * 1964-06-09
US3716583A (en) * 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4179515A (en) * 1975-02-12 1979-12-18 Orchimed S. A. Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4075000A (en) * 1975-05-27 1978-02-21 Eli Lilly And Company Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4304718A (en) * 1975-10-06 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4472309A (en) * 1975-10-06 1984-09-18 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4576753A (en) * 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4166907A (en) * 1976-11-01 1979-09-04 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) * 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
FR2403078A1 (fr) * 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
IT1157365B (it) * 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) * 1979-12-31 1981-04-07 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DE3107100A1 (de) * 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4500456A (en) * 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) * 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4534786A (en) * 1982-06-23 1985-08-13 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4443372A (en) * 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) * 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
CA1256650A (en) * 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
US4675399A (en) * 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
US4614614A (en) * 1983-03-28 1986-09-30 Ciba-Geigy Corporation Process for the manufacture of optically active azetidinones
WO1985004876A1 (en) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. 2-azetidinone derivatives and process for their preparation
US4576749A (en) * 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FR2561916B1 (fr) * 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) * 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) * 1984-09-17 1986-03-18 Merck & Co., Inc. 3-Hydroxy-3-aminoethyl β-lactams
US4620867A (en) * 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
EP0234484B1 (en) * 1986-02-19 1993-10-20 Sanraku Incorporated Novel azetidinone derivatives
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2598146B1 (fr) * 1986-04-30 1989-01-20 Rech Ind Nouveau procede de preparation de fibrates.
DE3621861A1 (de) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
JPS63156788A (ja) * 1986-12-22 1988-06-29 Sanraku Inc 光学活性アゼチジノン類
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US4879301A (en) * 1987-04-28 1989-11-07 Hoei Pharmaceutical Co., Ltd. Antiallergic and antiinflammatory benzothiazolinone derivatives
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5091525A (en) * 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) * 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (fr) * 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼａ↓２阻害物質
US5021461A (en) * 1989-07-26 1991-06-04 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP2640986B2 (ja) * 1990-11-08 1997-08-13 高砂香料工業株式会社 （１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
JP3144624B2 (ja) * 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
CN1342091A (zh) * 1998-12-23 2002-03-27 G.D.瑟尔有限公司 心血管指征的联合用药
CA2423141A1 (en) * 2000-09-27 2002-04-04 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
CA2431983C (en) * 2000-12-21 2010-06-08 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenylazetidinones, processes for their preparation, medicaments comprising these compounds and their use for treating impaired lipid metabolism
HUP0401073A2 (hu) * 2000-12-21 2004-09-28 Aventis Pharma Deutschland Gmbh. Difenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
CZ20032031A3 (cs) * 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
CA2434430A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
SK288217B6 (sk) * 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
MXPA03006727A (es) * 2001-01-26 2003-10-24 Schering Corp Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
AU2002251978B2 (en) * 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
WO2002081454A1 (en) * 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP1785144A2 (en) 2007-05-16
WO2002058733A2 (en) 2002-08-01
EP1785144A3 (en) 2007-05-23
CA2434033A1 (en) 2002-08-01
PT1363668E (pt) 2007-11-07
SI1363668T1 (sl) 2007-12-31
WO2002058733A9 (en) 2003-03-06
EP1363668B1 (en) 2007-08-15
CY1106915T1 (el) 2012-09-26
DE60221798T2 (de) 2008-06-05
AU2002241956A1 (en) 2002-08-06
AR035739A1 (es) 2004-07-07
JP2004521894A (ja) 2004-07-22
ES2287250T3 (es) 2007-12-16
WO2002058733A3 (en) 2003-06-26
US20030053981A1 (en) 2003-03-20
US20080261942A1 (en) 2008-10-23
EP1363668A2 (en) 2003-11-26
ATE369851T1 (de) 2007-09-15
DK1363668T3 (da) 2007-11-05
DE60221798D1 (de) 2007-09-27
WO2002058733B1 (en) 2003-08-14
TW200744638A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
MXPA03006631A (es) Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
WO2002058731A3 (en) Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
YU58603A (sh) Kombinacija aktivatora receptora aktiviranih peroksizom proliferatora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
WO2002058734A3 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
WO2005046797A3 (en) Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
WO2002058685A3 (en) Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
AP2003002890A0 (en) Therapeutic combinations for cardiovascular and inflammatory indications.
WO2005037259A3 (en) Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
MXPA05009501A (es) Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
TW200509937A (en) Novel compounds and their use in therapy
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
TW200500361A (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
WO2000038666A3 (en) A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
WO2005096704A3 (en) Cholesterol lowering composition
MXPA05009502A (es) Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1864680A3 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1859796A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
AU2003282035A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
ECSP034704A (es) Combinaciones de inhibidor(es) de la absorcion de esterol con midificador(es) sanguineos para tratar cuadros vasculares

Legal Events

Date Code Title Description
FG Grant or registration